Fibrinolytic system in atherosclerosis.
In this short review I have tried to report the literature findings and describe some of our observations on fibrinolysis and atherosclerosis. Although at this time it is difficult to state that diminished FA plays a pathogenic role in atherosclerosis, it certainly seems to represent a risk factor.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood* / Q000188:drug therapy; D001778:Blood Coagulation Disorders; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010960:Plasminogen Activators / Q000378:metabolism; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy; D013927:Thrombosis / Q000097:blood; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D005337:Fibrin; D010960:Plasminogen Activators